Andra AP fonden Purchases 5,500 Shares of United Therapeutics Co. (NASDAQ:UTHR)

Andra AP fonden raised its position in United Therapeutics Co. (NASDAQ:UTHR) by 9.0% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 66,600 shares of the biotechnology company’s stock after purchasing an additional 5,500 shares during the period. Andra AP fonden owned 0.15% of United Therapeutics worth $23,499,000 at the end of the most recent reporting period.

Other large investors have also recently bought and sold shares of the company. Newbridge Financial Services Group Inc. bought a new stake in shares of United Therapeutics during the 4th quarter worth $25,000. Brooklyn Investment Group bought a new position in United Therapeutics in the third quarter valued at $33,000. Capital Performance Advisors LLP bought a new position in United Therapeutics in the third quarter valued at $82,000. MassMutual Private Wealth & Trust FSB increased its stake in United Therapeutics by 31.9% in the fourth quarter. MassMutual Private Wealth & Trust FSB now owns 240 shares of the biotechnology company’s stock valued at $85,000 after acquiring an additional 58 shares during the last quarter. Finally, Jones Financial Companies Lllp increased its position in shares of United Therapeutics by 678.9% during the 4th quarter. Jones Financial Companies Lllp now owns 296 shares of the biotechnology company’s stock valued at $104,000 after purchasing an additional 258 shares during the last quarter. 94.08% of the stock is owned by institutional investors.

United Therapeutics Price Performance

Shares of United Therapeutics stock opened at $307.68 on Friday. The business’s 50 day simple moving average is $356.53 and its two-hundred day simple moving average is $360.45. The stock has a market capitalization of $13.82 billion, a P/E ratio of 13.51, a price-to-earnings-growth ratio of 0.97 and a beta of 0.57. United Therapeutics Co. has a one year low of $221.53 and a one year high of $417.82.

United Therapeutics (NASDAQ:UTHR) last posted its earnings results on Wednesday, February 26th. The biotechnology company reported $6.19 earnings per share (EPS) for the quarter, beating the consensus estimate of $6.10 by $0.09. United Therapeutics had a return on equity of 19.22% and a net margin of 40.31%. The firm had revenue of $735.90 million for the quarter, compared to analysts’ expectations of $734.74 million. During the same period in the previous year, the firm earned $4.36 earnings per share. Sell-side analysts expect that United Therapeutics Co. will post 24.48 earnings per share for the current fiscal year.

Insider Activity

In related news, Director Louis W. Sullivan sold 26,209 shares of United Therapeutics stock in a transaction that occurred on Wednesday, December 18th. The stock was sold at an average price of $373.22, for a total transaction of $9,781,722.98. Following the sale, the director now directly owns 5,051 shares in the company, valued at $1,885,134.22. The trade was a 83.84 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, COO Michael Benkowitz sold 10,000 shares of United Therapeutics stock in a transaction that occurred on Monday, December 30th. The shares were sold at an average price of $356.68, for a total value of $3,566,800.00. Following the sale, the chief operating officer now owns 2,577 shares in the company, valued at $919,164.36. This represents a 79.51 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders have sold 116,464 shares of company stock valued at $42,396,244. Company insiders own 11.90% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities analysts recently weighed in on the company. StockNews.com cut United Therapeutics from a “strong-buy” rating to a “buy” rating in a report on Thursday, February 27th. HC Wainwright reissued a “buy” rating and set a $425.00 price objective on shares of United Therapeutics in a report on Thursday, February 27th. Finally, UBS Group raised their price objective on United Therapeutics from $415.00 to $475.00 and gave the company a “buy” rating in a report on Wednesday, January 8th. One investment analyst has rated the stock with a sell rating, two have issued a hold rating and ten have issued a buy rating to the stock. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $388.25.

United Therapeutics Company Profile

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.